Sutro Biopharma (NASDAQ:STRO) Given New $55.00 Price Target at Deutsche Bank Aktiengesellschaft

Sutro Biopharma (NASDAQ:STRO) had its price target hoisted by Deutsche Bank Aktiengesellschaft from $51.00 to $55.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also weighed in on STRO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target for the company in a research report on Tuesday, January 20th. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $10.00 to $28.00 in a report on Tuesday. Wedbush reiterated a “neutral” rating and issued a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Finally, Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.29.

Sutro Biopharma Trading Down 0.3%

Shares of NASDAQ STRO opened at $23.50 on Wednesday. The company has a market cap of $199.99 million, a price-to-earnings ratio of -0.90 and a beta of 1.47. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54. The stock’s 50 day simple moving average is $18.61 and its 200 day simple moving average is $12.76.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. State of Tennessee Department of Treasury bought a new position in shares of Sutro Biopharma in the fourth quarter worth $86,000. Jane Street Group LLC bought a new stake in shares of Sutro Biopharma during the fourth quarter valued at about $265,000. Bridgeway Capital Management LLC lifted its holdings in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the period. ADAR1 Capital Management LLC bought a new position in Sutro Biopharma in the 4th quarter valued at about $776,000. Finally, Spruce Street Capital LP bought a new position in Sutro Biopharma in the 4th quarter valued at about $875,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Key Headlines Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.